Roche Cholesterol Gen.2 Cassette Recalled for Potential Drug Interference
Roche Diagnostics is recalling Cholesterol Gen.2 cassettes because Trinder reaction tests may yield falsely decreased results when specific drugs are present.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, but the hazard involves potential inaccurate test results (falsely decreased) due to drug interference rather than direct physical injury or reported illnesses, fitting the criteria for a moderate risk of adverse health consequences through misdiagnosis.
Plain-English summary
Roche Diagnostics Operations, Inc. is recalling the Cholesterol Gen.2 cassette (CHOL2), an in vitro diagnostic reagent system used for the quantitative determination of total cholesterol in serum and plasma. The product is intended for use on COBAS Integra 800 and 400 plus systems, cobas c111, and cobas c systems.
The recall is issued due to possible drug interference when using the Trinder reaction method on multiple Cobas Analyzers. Specifically, results of Trinder tests may be falsely decreased when run with urine samples (Creatinine plus and Uric Acid applications only) or blood samples collected before sufficient time has lapsed after the administration of the drugs Acetaminophen and N-acetylcysteine.
A total of 6,255 analytical units were distributed nationwide in the United States, including Puerto Rico. Affected catalog numbers include 04718917190, 03039773190, and 05168538190. Healthcare facilities and laboratories should contact Roche Diagnostics for further instructions on handling the recalled product.
The recalled product
- Product
- Cholesterol Gen.2. The cassette COBAS Integra Cholesterol Gen.2 (CHOL2) contains an in vitro diagnostic reagent system intended for use on COBAS Integra 800 and 400 plus systems, cobas c111, and cobas c systems for the quantitative determination of total cholesterol in serum a
- Manufacturer
- Roche Diagnostics Operations, Inc.
- Affected units
- 6,255
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Catalog Numbers: 04718917190
- 03039773190
- 05168538190
- 03039773190.
Distribution
Part of a larger recall action
This product is one of 12 recalled by Roche Diagnostics Operations, Inc. under a single FDA (Devices) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 12 products in this recall →Related recalls
Same manufacturer · Roche Diagnostics Operations, Inc.
See all →- HighRoche cobas analyzer may repeat previous results for spline calibrated assays
FDA (Devices) · 2026-03-11
- HighThyroid receptor immunoassay recalled over variable results across instrument platforms
FDA (Devices) · 2026-01-14
- HighMedical Device Homocysteine Test Assay Recalled for Calibration Defects
FDA (Devices) · 2024-11-27
- HighRoche Creatine Kinase test reagents recalled for calibration errors
FDA (Devices) · 2024-10-02
- HighRoche Tina-quant D-Dimer Test System Recalled for Inaccurate Results
FDA (Devices) · 2023-11-29
Same hazard · drug interference
See all →- HighRAPIDPOINT 500 Blood Gas System: Drug Interference May Cause False Sodium Readings
FDA (Devices) · 2023-12-06
- HighRAPIDPOINT 500e Blood Gas System Recalled Due to Drug Interference
FDA (Devices) · 2023-12-06
- HighMedtronic Enlite Glucose Sensor Recall Due to Hydroxyurea Interference
FDA (Devices) · 2021-05-26
- ModerateOrtho VITROS Chemistry TP Slides Recalled for Eltrombopag Interference
FDA (Devices) · 2021-01-20
- HighOrtho-Clinical Diagnostics Recalls VITROS TBIL Slides Due to Etrombopag Interference
FDA (Devices) · 2020-09-02